摘要
目的:探讨参芪延肾方对慢性肾脏病患者半乳糖缺陷IgA1(Gd-IgA1)、晚期糖基化终产物(AGEs)水平及微炎性反应状态的影响。方法:选择慢性肾脏病患者96例,随机分为对照组和研究组各48例。其中两组患者均给予常规治疗,对照组给予醋酸泼尼松片治疗,观察组在此基础上给予参芪延肾方治疗,比较两组患者治疗前后血液流变学指标、肾功能指标以及血清Gd-IgA1、AGEs水平、炎症水平变化,观察两组患者临床治疗效果差异。结果:治疗8周后,两组全血低切、全血高切、血浆黏度值均明显降低,研究组更明显(P<0.05)。用药8周后,两组尿微量白蛋白(UmAlb)、24 h尿微量白蛋白排泄率(UAER)、血肌酐(Scr)水平降低,研究组更明显(P<0.05)。治疗8周后,两组血清Gd-IgA1、AGEs、C-反应蛋白(CRP)、白介素-6(IL-6)、白介素-8(IL-8)水平下降,研究组低于对照组(P<0.05)。研究组总有效率明显高于对照组(P<0.05)。结论:参芪延肾方可改善慢性肾脏病患者肾功能,降低Gd-IgA1、AGEs水平,减轻微炎性反应状态。
Objective:To investigate the effects of Shenqi Yanshen recipe on the levels of galactose deficient IgA1(Gd-IgA1),advanced glycation end products(AGEs)and micro inflammatory response in patients with chronic kidney disease.Methods:A total of 96 patients with chronic kidney disease were randomly divided into control group(n=48)and study group(n=48).The two groups were given routine treatment,the control group was treated with prednisone acetate tablets,and the observation group was treated with Shenqi Yanshen recipe on the basis of the control group.The changes of hemorheological indexes,renal function indexes,serum Gd-IgA1,AGEs levels and inflammation levels before and after treatment were compared between the two groups,and the differences of clinical treatment effects between the two groups were observed.Results:After 8 weeks of treatment,the values of LS,HS and PV decreased significantly in the two groups,especially in the study group(P<0.05).After 8 weeks of treatment,the levels of Umalb,UAER and Scr decreased in the two groups,especially in the study group(P<0.05).After 8 weeks of treatment,the levels of serum Gd-IgA1,AGEs,CRP,IL-6 and IL-8 in the study group were lower than those in the control group(P<0.05).The total effective rate of the study group was significantly higher than that of the control group(P<0.05).Conclusion:Shenqi Yanshen recipe can improve renal function,reduce the levels of Gd-IgA1 and AGEs,and reduce the state of micro inflammatory reaction in patients with chronic nephritis.It has satisfactory clinical effect and is worthy of popularization and application.
作者
齐宁
宋姝西
刘香玉
杨宏伟
王志文
刘宝义
QI Ning;SONG Shuxi;LIU Xiangyu;YANG Hongwei;WANG Zhiwen;LIU Baoyi(Affiliated Hospital of North China University of Technology,Tangshan 063000,China)
出处
《陕西中医》
CAS
2022年第5期596-599,共4页
Shaanxi Journal of Traditional Chinese Medicine
基金
河北省中医药管理局科研计划项目(2020218)。